甲氨蝶呤在真实世界单中心巨细胞动脉炎队列中的疗效与耐受性
该研究从超过500例巨细胞动脉炎患者的单中心数据库中回顾性选取2010至2020年间接受甲氨蝶呤治疗的49例患者,评估其适应证、疗效与耐受性。中位随访84个月,甲氨蝶呤治疗期间51%患者复发,停药后44%复发;49%患者得以停用糖皮质激素,但甲氨蝶呤引入前后累积糖皮质激素剂量无显著差异。作者认为甲氨蝶呤对复发有适度获益,但未观察到糖皮质激素节约效应。
要点
- 甲氨蝶呤治疗期间25例(51%)复发,停药后18/41例(44%)复发。
- 40例甲氨蝶呤前复发者中26例(65%)在引入甲氨蝶呤后再次复发。
- 24例(49%)在甲氨蝶呤后中位20.5个月停用糖皮质激素,累积剂量无显著差异。
核心结论
- 作者认为真实世界研究显示甲氨蝶呤对巨细胞动脉炎患者复发有适度获益,但未观察到糖皮质激素节约效应。
- 作者指出需要其他研究评估在依据近期推荐调整糖皮质激素管理的患者中的糖皮质激素节约效应。
研究设计与样本
- 从超过500例巨细胞动脉炎患者的单中心数据库中回顾性选取2010至2020年间接受甲氨蝶呤治疗的49例患者。
- 记录甲氨蝶呤治疗前、治疗期间及治疗后的累积糖皮质激素剂量、复发次数及糖皮质激素相关不良事件。
- 分别分析甲氨蝶呤的3个主要适应证:疾病复发、糖皮质激素节约策略及巨细胞动脉炎表现。
主要发现
- 中位随访84[10-255]个月,甲氨蝶呤治疗期间25例(51%)复发,停药后18/41例(44%)复发。
- 40例甲氨蝶呤前复发患者中,26例(65%)在引入甲氨蝶呤后出现新发复发。
- 引入甲氨蝶呤后,24例(49%)在中位20.5[7-64]个月停用糖皮质激素。
- 甲氨蝶呤引入前后累积糖皮质激素剂量无显著差异,总糖皮质激素剂量为14.7[1.05-69.4]克。
- 末次随访时41例停用甲氨蝶呤,其中13例(32%)因临床生物学缓解、12例(30%)因治疗失败、15例(36%)因副作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为单中心回顾性研究,样本量为49例。
- 作者指出需要其他研究评估在依据近期推荐调整糖皮质激素管理的患者中的糖皮质激素节约效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the indications, efficiency and tolerance profiles of methotrexate (MTX) in patients with giant cell arteritis (GCA) in a real-life setting. METHODS: From a monocentric database of >500 GCA patients, we retrospectively selected 49 patients who received MTX between 2010 and 2020. Cumulative glucocorticoid (GC) doses, the number of relapses and GC-related adverse events were recorded before, during and after MTX. We separately analyzed the 3 main indications of MTX, i.e., disease relapse, GC-sparing strategy, and GCA presentation. RESULTS: With a median follow-up of 84 [10-255] months, 25 (51%) and 18/41 (44%) patients relapsed during MTX treatment and after its discontinuation, respectively. Among the 40 patients who relapsed before MTX, 26 (65%) experienced a new relapse after MTX introduction. Once MTX was introduced, 24 (49%) patients were able to discontinue GC after 20.5 [7-64] months. No significant difference in cumulative GC doses were noted before and after MTX introduction with a total GC dose of 14.7 [1.05-69.4] grams. At the last follow-up, MTX was discontinued in 41 patients, including 13 (32%) due to clinicobiological remission, 12 (30%) due to treatment failure and 15 (36%) due to side effects. CONCLUSION: Our real-life study showed a modest beneficial effect of MTX on relapse in patients with GCA. However, we did not observe any GC-sparing effect in this study. Other studies are needed to assess the GC-sparing effect in patients in whom GC management is adapted from recent recommendations.
引用
- Lavergne A, Dumont A, Deshayes S, et al. Efficacy and tolerance of methotrexate in a real-life monocentric cohort of patients with giant cell arteritis. Semin Arthritis Rheum. 2023. PMID: 36963127. doi:10.1016/j.semarthrit.2023.152192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。